The effects of protein supplementation with or without Urolithin A during single-leg immobilization

Submission date	Recruitment status No longer recruiting	[X] Prospectively registered		
08/02/2023		☐ Protocol		
Registration date	Overall study status	Statistical analysis plan		
09/02/2023	Completed	☐ Results		
Last Edited 28/02/2025	Condition category Musculoskeletal Diseases	Individual participant data		
		[X] Record updated in last year		

Plain English summary of protocol

Background and study aims

There are times in life when we cannot use our muscles, such as during illness or injury. Muscle and mitochondria (the 'energy factory' in our cells) health decline very quickly when we cannot use our muscles, but certain foods can help reduce these declines. Recent research suggests that Urolithin A, which is a natural compound that can be produced after eating pomegranates, nuts, and berries, improves muscle health. In this study, we aim to investigate if a protein beverage (standard care during disuse) with or without Urolithin A can reduce or prevent the loss of muscle health while wearing a knee brace (muscle disuse).

Who can participate?

We are recruiting healthy male volunteers aged 18-30 years.

What does the study involve?

This study involves consuming a randomly assigned supplement for 4 weeks, including 2 weeks of wearing a knee brace.

What are the possible benefits and risks of participating?

There are no proposed benefits to you as the subject of this study. However, the findings of this study may contribute to the development of nutritional interventions that prevent or attenuate the loss of skeletal muscle mass in various clinical scenarios including aging, bed rest, surgery, cachexia, and renal failure.

As with any research, there are risks of participating such as during blood sampling or muscle biopsies. The researcher team has done everything possible to mitigate any risks and will gladly provide further information if requested.

Where is the study run from? McMaster University in Hamilton, Ontario, Canada

When is the study starting and how long is it expected to run for? April 2021 to December 2023

Who is funding the study?
This study is funded by Nestle SA (Switzerland)

Who is the main contact? Stuart Phillips, phillis@mcmaster.ca

Contact information

Type(s)

Scientific, Principal investigator

Contact name

Dr Stuart Phillips

ORCID ID

https://orcid.org/0000-0002-1956-4098

Contact details

1280 Main Street West
Department of Kinesiology
McMaster University
Hamilton
Canada
L8S 4K1
+1 (905) 525-9140 ext. 24465
phillis@mcmaster.ca

Additional identifiers

Clinical Trials Information System (CTIS)

Nil known

ClinicalTrials.gov (NCT)

NCT05814705

Protocol serial number

13783

Study information

Scientific Title

Comparison of high-protein formulation with/without urolithin a during a unilateral knee immobilization: a pilot proof-of-concept trial

Study objectives

- 1. PRO+UA will mitigate reductions in maximal mitochondrial respiration compared to PRO during immobilization.
- 2. PRO+UA will alter gene expression compared to PRO during immobilization.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 30/11/2022, Hamilton Integrated Research Ethics Board (293 Wellington St. N., Suite 120 Hamilton, ON, Canada L8L 8E7; +1 905-521-2100 Ext. 42013; eREBhelpdesk@hhsc.ca), ref: #13783

Study design

Single-centre interventional double-blinded randomized trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Disuse-induced muscle atrophy in healthy young adults

Interventions

Participants will be randomized (computer-generated) to either active comparator (protein) or treatment (protein plus Urolithin A) group.

Participants will sequentially complete the three phases of this study:

- 1. RUN-IN phase participants continue habitual lifestyle (1 week)
- 2. IMMOBILIZATION phase participants undergo 2 weeks of unilateral knee immobilization
- 3. RECOVERY phase participants return to habitual lifestyle (1 week)

Measurements will be taken at baseline and the end of each phase.

Participants will consume their randomly assigned beverage (ready-to-drink supplement; 20 grams of protein with or without 1000 mg Urolithin A) during all three phases.

Intervention Type

Supplement

Primary outcome(s)

- 1. Maximal mitochondrial respiration and mitochondrial ADP sensitivity (Oroboros O2k; measured at baseline and the end of each phase)
- 2. Gene expression (measured at baseline and the end of each phase)

Key secondary outcome(s))

- 1. Skeletal muscle fractional synthetic rate (deuterated water; measured at baseline and the end of each phase)
- 2. Leg muscle strength (biodex dynamometer; measured at baseline and the end of each phase)
- 3. Quadriceps volume and cross-sectional area (magnetic resonance imaging; measured at baseline and the end of each phase)
- 4. Physical activity level (accelerometry; measured at baseline and the end of each phase)
- 5. Metabolomics (plasma; measured at baseline and the end of each phase)

Completion date

Eligibility

Key inclusion criteria

- 1. Men aged 18-30 years
- 2. Healthy, non-smoking
- 3. BMI between 20 and 30 kg/m²
- 4. No orthopedic issues that would preclude participation in the knee bracing protocol
- 5. Not taking any medication or with any medical condition that, in the opinion of the investigators, would compromise the study outcome or the safety of the research participant
- 6. Provide informed consent
- 7. Understand COVID-19 risks and procedures for in person research and sign Information Letter: COVID-19 Risks and Procedures for In-Person Research at McMaster University

Participant type(s)

Healthy volunteer

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Upper age limit

30 years

Sex

Male

Total final enrolment

24

Key exclusion criteria

- 1. Subject has any concurrent medical, orthopedic, or psychiatric requirements that, in the opinion of the investigators, would compromise their ability to comply with the study requirements
- 2. Clinically significant abnormal laboratory results at screening
- 3. Participation in a clinical research trial within 30 days before randomization
- 4. Allergy or sensitivity to study ingredients
- 5. Individuals who are cognitively impaired and/or who are unable to give informed consent
- 6. Any other condition that, in the opinion of the investigators, may adversely affect the subject's ability to complete the study or its measures or may pose a significant risk to the subject
- 7. Any cachexia-related condition or any genetic muscle diseases or disorders
- 8. Current gastrointestinal condition that could interfere with the study (e.g., IBS/IBD, diarrhea, acid reflux disease, dysphagia, etc.)
- 9. Excessive alcohol consumption (>21 units/week) and/or a smoker (cigarettes or vaping)

10. Concomitant use of corticosteroids, antibiotics, any anabolic steroid, creatine, whey protein supplements, casein, branched-chain amino acids (BCAAs) or any other NHP, medication or supplement used for muscle strengthening/building within 45 days prior to screening 11. Contraindications to an MRI scan (metal implants, metal-based ink tattoo)

Date of first enrolment 24/02/2023

Date of final enrolment 01/04/2024

Locations

Countries of recruitmentCanada

Study participating centre McMaster University 1280 Main Street West Hamilton Canada L8S 4L8

Sponsor information

Organisation

McMaster University

ROR

https://ror.org/02fa3aq29

Funder(s)

Funder type

Industry

Funder Name

Nestlé SA

Results and Publications

Individual participant data (IPD) sharing plan

The data-sharing plans for the current study are unknown and will be made available at a later date.

IPD sharing plan summary

Data sharing statement to be made available at a later date

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes